1. Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015; 33: 1770-1778. doi: 10.1200/JCO.2014.59.7930
2. Pollom EL, Alagappan M, von Eyben R, et al. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: Outcomes and toxicity. Int J RadiatOncol Biol Phys. 2014; 90(4): 918-925. doi: 10.1016/j.ijrobp.2014.06.066
3. Burris HA, Moore MJ, Andersen J, et al. Improvements line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997; 15: 2403-2413. doi: 10.1200/JCO.1997.15.6.2403
4. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008; 19: 1592-1599. doi: 10.1093/annonc/mdn281
5. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-1703. doi: 10.1056/NEJMoa1304369
6. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825. doi: 10.1056/NEJMoa1011923
7. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabinebased or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial. Lancet Oncol. 2013; 14: 317-326. doi: 10.1016/S1470- 2045(13)70021-4
8. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 1017-1021. doi: 10.1016/j. ijrobp.2003.11.004
9. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009; 115: 665-672. doi: 10.1002/cncr.24059
10. Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010; 78: 735-742. doi: 10.1016/j. ijrobp.2009.08.046
11. Mahadevan A, Miksad R, Goldstein M, et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011; 81: e615-622. doi: 10.1016/j.ijrobp.2011.04.045
12. Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013; 86: 516-522. doi: 10.1016/j.ijrobp.2013.02.022
13. Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015; 121: 1128-1137. doi: 10.1002/cncr.29161
14. Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015; 54: 979-985. doi: 10.3109/0284186X.2015.1004367
15. Chhabra A, Kaiser A, Regine WF, Chuong MD. The expanding role of stereotactic body radiation therapyfor pancreatic cancer: A review of the literature. Transl Cancer Res. 2015; 4(6): 659-670. doi: 10.3978/j.issn.2218-676X.2015.11.01
16. Moningi S, Marciscano AE, Rosati LM, et al. Stereotactic body radiation therapy in pancreatic cancer: The new frontier. Expert Rev Anticancer Ther. 2014; 14: 1461-1475. doi: 10.1586/14737140.2014.952286
17. Moningi S, Dholakia AS, Raman SP, et al. The role of stereotactic body radiation therapy for pancreatic cancer: A single-institution experience. Ann Surg Oncol. 2015; 22: 2352-2358. doi: 10.1245/ s10434-014-4274-5
18. Rajagopalan MS, Heron DE, Wegner RE, et al. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locallyadvanced pancreatic cancer. Radiat Oncol. 2013; 8: 254. doi: 10.1186/1748-717X-8-254
19. He J, Moningi S, Blair AB, et al. Surgical outcomes of patients with pancreatic cancer treated with stereotactic body radiation therapy. J Clin Oncol. 2015; 33: abstr 341. doi: 10.1200/jco.2015.33.3_ suppl.341
20. Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012; 99(8): 1036-1049. doi: 10.1002/bjs.8734
21. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection inpancreatic cancer. Br J Surg. 2006; 93: 1232-1237. doi: 10.1002/bjs.5397
22. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: The Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009; 11: 18-24. doi: 10.1111/j.1477-2574.2008.00013.x
23. Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008; 15: 1651-1660. doi: 10.1245/s10434-008-9839-8
24. Campbell F, Smith RA, Whelan P, et al. Classification of R1 resections forpancreatic cancer: The prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009; 55: 277-283. doi: 10.1111/j.1365-2559.2009.03376.x
25. Jamieson NB, Foulis AK, Oien KA, et al. Positive immobilization margins alone donot influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2010; 251: 1003-1010. doi: 10.1097/SLA.0b013e3181d77369
26. Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012; 99: 1036- 1049. doi: 10.1002/bjs.8734
27. Colbert LE, Hall WA, Nickleach D, Switchenko J, Kooby DA, Landry JC. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Cancer. 2014; 120(4): 499-506. doi: 10.1002/cncr.28530
28. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patientswith resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial. Lancet. 2017; 389(10073): 1011-1024. doi: 10.1016/S0140-6736(16)32409-6
29. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3496-3502. doi: 10.1200/JCO.2007.15.8634
30. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3487-3495. doi: 10.1200/JCO.2007.15.8642
31. Cloyd JM, Chen HC, Wang X, et al. Chemotherapy versus chemoradiation as preoperative therapy for resectable pancreatic ductal adenocarcinoma: A propensity score adjusted analysis. Pancreas. 2019; 48(2): 216-222. doi: 10.1097/MPA.0000000000001231
32. Katz MH, Wang H, Balachandran A, et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localizedpancreatic cancer. J Gastrointest Surg. 2012; 16: 68-78; discussion 78-79. doi: 10.1007/s11605-011-1748-7
33. Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017; 18: 1040-1048. doi: 10.1016/S1470- 2045(17)30414-X
34. Aridgides P, Bogart J. Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin. 2016; 26: 261- 269. doi: 10.1016/j.thorsurg.2016.04.008
35. Qiu H, Moravan MJ, Milano MT, Usuki KY, Katz AW. SBRT for hepatocellular carcinoma: 8-year experience from a regional transplant center. J Gastrointest Cancer. 2018; 49(4): 463-469. doi: 10.1007/s12029-017-9990-1
36. Kishan AU, King CR. Stereotactic body radiotherapy for lowand intermediate-risk prostate cancer. Semin Radiat Oncol. 2017; 27: 268-278. doi: 10.1016/j.semradonc.2017.02.006
37. Baliga S, Kabarriti R, Ohri N, et al. Stereotactic body radiotherapy for recurrent head and neck cancer: A critical review. Head Neck. 2017; 39: 595-601. doi: 10.1002/hed.24633
38. Kim MS, Kim W, Park IH, et al. Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery. Radiat Oncol J. 2015; 33: 265-275. doi: 10.3857/roj.2015.33.4.265
39. Song CW, Lee YJ, Griffin RJ, et al. Indirect tumor cell death after high-dose hypofractionated irradiation: Implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys. 2015; 93: 166-172. doi: 10.1016/j. ijrobp.2015.05.016
40. Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012; 177: 311-327. doi: 10.1667/rr2773.1
41. Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: Are more than the 5 R’s involved? Int J Radiat Oncol Biol Phys. 2014; 88: 254-262. doi: 10.1016/j.ijrobp.2013.07.022
42. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004; 432: 332-337. doi: 10.1038/nature03096
43. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; 6: 392-401. doi: 10.1038/nrc1877
44. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle. 2006; 5: 1597-1601. doi: 10.4161/cc.5.15.3112
45. Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol. 2010; 21: 19-25. doi: 10.1016/j.semcdb.2009.10.002
46. Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol. 2011; 89: 31-39. doi: 10.1189/jlb.0310182
47. Gaggioli C, Hooper S, Hidalgo-Carcedo C, et al. Fibroblastled collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007; 9: 1392-1400. doi: 10.1038/ncb1658
48. Arnold KM, Flynn NJ, Raben A, et al. The impact of radiation on the tumor microenvironment: Effect of dose and fractionation schedules. Cancer Growth Metastasis. 2018; 11: 1179064418761639. doi: 10.1177/1179064418761639
49. Maeda A, Chen Y, Bu J, Mujcic H, Wouters BG, DaCosta RS. In vivo imaging reveals significant tumor vascular dysfunction and increased tumor hypoxia-inducible factor-1α expression induced by high single-dose irradiation in a pancreatic tumor model. Int J Radiat Oncol Biol Phys. 2017; 97: 184-194. doi: 10.1016/j.ijrobp.2016.09.005
50. Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014; 41: 843-852. doi: 10.1016/j.immuni.2014.10.019
51. Baird JR, Friedman D, Cottam B, et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 2016; 76: 50-61. doi: 10.1158/0008-5472.CAN-14-3619
52. Perry AK, Chen G, Zheng D, Tang H, Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res. 2005; 15: 407-422. doi: 10.1038/sj.cr.7290309
53. Prakash H, Klug F, Nadella V, Mazumdar V, Schmitz-Winnenthal H, Umansky L. Low doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retuning tumor-associated macrophages: Lesson from insulinoma. Carcinogenesis. 2016; 37: 301-313. doi: 10.1093/carcin/bgw007
54. Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an INOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013; 24: 589-602. doi: 10.1016/j.ccr.2013.09.014
55. Chiang CS, Fu SY, Wang SC, et al. Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol. 2012; 2: 89. doi: 10.3389/fonc.2012.00089
56. Okubo M, Kioi M, Nakashima H, et al. M2-polarized macrophages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation. Sci Rep. 2016; 6: 27548. doi: 10.1038/srep27548
57. Seifert L, Werba G, Tiwari S, et al. Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice. Gastroenterology. 2016; 150: 1659.e5-1672.e5. doi: 10.1053/j.gastro.2016.02.070
58. Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016; 4: 51. doi: 10.1186/s40425-016-0156-7
59. Berberat PO, Kunzli BM, Gulbinas A, et al. An audit of outcomes of a series of periampullary carcinomas. Eur J SurgOncol. 2009; 35: 187-191. doi: 10.1016/j.ejso.2008.01.030
60. Lafaro KJ, Melstrom LG. The paradoxical web of pancreatic cancer tumor microenvironment. Am J Pathol. 2019; 189(1): 44-57. doi: 10.1016/j.ajpath.2018.09.009